This is a plain language summary of a study called CodeBreaK 100. The CodeBreaK 100 study included patients with non-small-cell lung cancer that had spread outside the lung (advanced). Lung cancer is one of the most common forms of cancer.CodeBreaK 100 specifically looked at patients with a particular change (mutation) in the KRAS gene resulting in the mutated protein called KRAS G12C. The KRAS G12C mutation can lead to development and growth of lung cancer.This Plain Language Summary of Publication article from Future Oncology summarises the results of a study called CodeBreaK 100, the study specifically looked at patients with a particular change in the KRAS gene, resulting in a mutated protein called KRAS G12C. The mutation can lead to the development and growth of lung cancer. The CodeBreaK 100 study looked at the safety and effectiveness of advanced non-small-cell lung cancer.

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100′ and was published in Journal of Clinical Oncology. 

Visit ASCO Publications using the link to read the original article.